A Case of Metastatic Castration‐Resistant Prostate Cancer With <i>RAD54L</i> Mutation Responding to Niraparib
The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104).
Authors
- Katsutoshi Oda (ORCID: https://orcid.org/0000-0002-2468-9573)
- Hidenori Kage (ORCID: https://orcid.org/0000-0003-3658-4442)
- Yusuke Sato (ORCID: https://orcid.org/0000-0002-6239-6050)
- Masaki Nakamura (ORCID: https://orcid.org/0000-0002-7473-3325)
- Kousuke Watanabe (ORCID: https://orcid.org/0000-0003-4670-3679)
- Yuta Yamada (ORCID: https://orcid.org/0000-0002-9698-4301)
- Haruki Kume (ORCID: https://orcid.org/0000-0001-9841-0857)
- Chiharu Tanai
- Kuniko Sunami (ORCID: https://orcid.org/0000-0002-7137-5649)
- Yoichi Fujii
Institutions
- Bunkyo University (JP)
- NTT Medical Center (JP)
- National Cancer Center (US)
- Tokyo Metropolitan Tama Medical Center (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1002/iju5.70093
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00